Literature DB >> 20231296

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.

Kathryn G Foster1, Diane C Fingar.   

Abstract

The mammalian target of rapamycin (mTOR) protein kinase responds to diverse environmental cues to control a plethora of cellular processes. mTOR forms the catalytic core of at least two distinct signaling complexes known as mTOR complexes 1 and 2. Differing sensitivities to the mTOR inhibitor rapamycin, unique partner proteins, distinct substrates, and unique cellular functions distinguish the complexes. Here, we review recent progress in our understanding of the regulation and function of mTOR signaling networks in cellular physiology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231296      PMCID: PMC2863215          DOI: 10.1074/jbc.R109.094003

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  99 in total

1.  regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis.

Authors:  Jae Eun Kim; Jie Chen
Journal:  Diabetes       Date:  2004-11       Impact factor: 9.461

2.  Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development.

Authors:  Yann-Gaël Gangloff; Matthias Mueller; Stephen G Dann; Petr Svoboda; Melanie Sticker; Jean-Francois Spetz; Sung Hee Um; Eric J Brown; Silvia Cereghini; George Thomas; Sara C Kozma
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

3.  mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells.

Authors:  Mirei Murakami; Tomoko Ichisaka; Mitsuyo Maeda; Noriko Oshiro; Kenta Hara; Frank Edenhofer; Hiroshi Kiyama; Kazuyoshi Yonezawa; Shinya Yamanaka
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

4.  mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E.

Authors:  Diane C Fingar; Celeste J Richardson; Andrew R Tee; Lynn Cheatham; Christina Tsou; John Blenis
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

5.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

Authors:  D D Sarbassov; Siraj M Ali; Do-Hyung Kim; David A Guertin; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Curr Biol       Date:  2004-07-27       Impact factor: 10.834

Review 6.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

7.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Authors:  Estela Jacinto; Robbie Loewith; Anja Schmidt; Shuo Lin; Markus A Rüegg; Alan Hall; Michael N Hall
Journal:  Nat Cell Biol       Date:  2004-10-03       Impact factor: 28.824

8.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.

Authors:  Sung Hee Um; Francesca Frigerio; Mitsuhiro Watanabe; Frédéric Picard; Manel Joaquin; Melanie Sticker; Stefano Fumagalli; Peter R Allegrini; Sara C Kozma; Johan Auwerx; George Thomas
Journal:  Nature       Date:  2004-08-11       Impact factor: 49.962

9.  Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function.

Authors:  Noriko Oshiro; Ken-ichi Yoshino; Sujuti Hidayat; Chiharu Tokunaga; Kenta Hara; Satoshi Eguchi; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Genes Cells       Date:  2004-04       Impact factor: 1.891

10.  Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status.

Authors:  Susan W Y Cheng; Lee G D Fryer; David Carling; Peter R Shepherd
Journal:  J Biol Chem       Date:  2004-02-17       Impact factor: 5.157

View more
  223 in total

1.  Insulin action on protein synthesis and its association with eIF5A expression and hypusination.

Authors:  André Ricardo Gomes de Proença; Karina Danielle Pereira; Leticia Meneguello; Leticia Tamborlin; Augusto Ducati Luchessi
Journal:  Mol Biol Rep       Date:  2018-12-05       Impact factor: 2.316

Review 2.  Tumor hypoxia and genetic alterations in sporadic cancers.

Authors:  Minoru Koi; Clement R Boland
Journal:  J Obstet Gynaecol Res       Date:  2011-01-27       Impact factor: 1.730

3.  Providing the TORC for cell cycle progression in neoplastic mast cells.

Authors:  Daniel Smrž; Todd M Wilson; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

4.  mTOR activity under hypoxia.

Authors:  Douangsone D Vadysirisack; Leif W Ellisen
Journal:  Methods Mol Biol       Date:  2012

5.  CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling.

Authors:  Javier Palazuelos; Zaira Ortega; Javier Díaz-Alonso; Manuel Guzmán; Ismael Galve-Roperh
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

Review 6.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

7.  Rag GTPases and AMPK/TSC2/Rheb mediate the differential regulation of mTORC1 signaling in response to alcohol and leucine.

Authors:  Ly Q Hong-Brown; C Randell Brown; Abid A Kazi; Maithili Navaratnarajah; Charles H Lang
Journal:  Am J Physiol Cell Physiol       Date:  2012-03-21       Impact factor: 4.249

8.  AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation.

Authors:  Wilfred Lieberthal; Leiqing Zhang; Vimal A Patel; Jerrold S Levine
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

9.  Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.

Authors:  Wei Chen; Qi-Da Hu; Xue-Feng Xia; Chao Liang; Hao Liu; Qi Zhang; Tao Ma; Feng Liang; Ting-Bo Liang
Journal:  Cancer Biol Ther       Date:  2014-05-06       Impact factor: 4.742

10.  Liver mTOR controls IGF-I bioavailability by regulation of protein kinase CK2 and IGFBP-1 phosphorylation in fetal growth restriction.

Authors:  Majida Abu Shehab; Ian Damerill; Tong Shen; Fredrick J Rosario; Mark Nijland; Peter W Nathanielsz; Amrita Kamat; Thomas Jansson; Madhulika B Gupta
Journal:  Endocrinology       Date:  2014-01-17       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.